The role that changes in DNA methylation and histone modifications have in human malignancies is poorly understood. p300 and CREB-binding protein (CBP), two distinct but highly homologous lysine acetyltransferases, are mutated in several cancers, suggesting their role as tumor suppressors. In the current study, we found that deletion of p300, but not CBP, markedly accelerated the leukemogenesis of Nup98-HoxD13 (NHD13) transgenic mice, an animal model that phenotypically copies human myelodysplastic syndrome (MDS). p300 deletion restored the ability of NHD13 expressing hematopoietic stem and progenitor cells (HSPCs) to self-renew in vitro, and to expand in vivo, with an increase in stem cell symmetric self-renewal divisions and a decrease in apoptosis. Furthermore, loss of p300, but not CBP, promoted cytokine signaling, including enhanced activation of the MAPK and JAK/STAT pathways in the HSPC compartment. Altogether, our data indicate that p300 has a pivotal role in blocking the transformation of MDS to acute myeloid leukemia, a role distinct from that of CBP.
INTRODUCTION
Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoiesis, characterized by inefficient hematopoiesis with bone marrow dysplasia, peripheral blood cytopenias and a predisposition to progress to acute myeloid leukemia (AML). 1 Considering the therapeutic response of MDS to DNA hypomethylating agents, and the recurrent somatic mutations found in epigenetic modifiers, including ASXL1, TET2 and DNMT3A, 2,3 many cases of MDS appear to represent an epigenetic disease.
The histone lysine acetyltransferases (KATs), p300 and its homolog CBP (CREB-binding protein), function primarily as transcriptional co-factors for a number of nuclear proteins, including MYC, p53 and E2F. 4 Both p300 and CBP have been implicated in tumorigenesis. For example, germline mutations that disrupt p300 and CBP are responsible for some cases of Rubinstein-Taybi syndrome, a genetic disorder with increased predisposition to develop tumors of neural and hematopoietic origins. 5 Somatic, loss-of-function mutations in p300 and CBP are found in lymphomas and some solid tumors, including colorectal cancer and gastric cancer. 6 Although rare, chromosomal translocations, t(8;16) and t (8;22) , that fuse amino terminus of CREBBP (the gene-encoding CBP) or EP300 (the gene-encoding p300) to MOZ (the gene-encoding monocytic leukemia zinc-finger protein) are found in the M4/M5 subtype of AML. 7, 8 These translocations generate haploinsufficiency for CBP and p300, in addition to the gain-of-functions intrinsic to the fusion proteins they generate.
The function of p300/CBP in normal and malignant hematopoiesis has been studied in genetic mouse models. Both p300 −/− and CBP −/− mice exhibit embryonic lethality due to similar defects in growth and neural tube closure.
9 p300 or CBP deficiency impairs the self-renewal and the differentiation of hematopoietic stem cells in mice. 10, 11 In addition, heterozygous CBP knockout mice, but not heterozygous p300 knockout mice, develop hematopoietic malignancies, 12 indicating the non-redundant function of these two lysine acetyltransferases in leukemogenesis.
Although the above evidence suggests a tumor suppressor role of p300/CBP, we previously reported that p300 acetylates the AML1-Eight Twenty One (ETO) leukemogenic fusion protein and is required for AML1-ETO-driven AML development, 13 suggesting an oncogene-specific and cell context-dependent function of p300 in tumorigenesis. Genetic studies on MDS and MDS-related AML patients revealed various mutations, deletions and translocations in Ep300 gene. [14] [15] [16] [17] The mutation rate of Ep300 ranges from 2 to 7% in different cohorts of patients in these studies. Here we examined the role of p300 and CBP in the pathogenesis of MDSderived AML; using Mx1Cre-induced deletion of Ep300 or CREBBP in Nup98-HoxD13 (NHD13) transgenic mice. We found that loss of p300, but not CBP, significantly accelerated the onset of AML and triggered hematopoietic stem and progenitor cell (HSPC) expansion. The early onset of transformation in p300-deleted NHD13 mice is associated with an enhanced 'cytokine signaling profile', affecting both MAPK and JAK/STAT pathways. Overall, our results indicate that p300, but not CBP, functions as a powerful tumor suppressor in the progression of NHD13-driven MDS to AML.
MATERIALS AND METHODS Mice
CD45.1 B6SJL mice and Mx1Cre mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). NHD13 transgenic mice (kindly provided by Perter Aplan, National Institute of Health), p300 flox/flox mice and CBP
Flow analysis and cell sorting
Single-cell suspensions were prepared from bone marrow (BM) and spleen cells as previously described. 19 APC-c-kit, phycoerythrin-Cy7-Sca-1 and Pacblue-Ki67 antibodies were purchased from eBioscience (San Diego, CA, USA). APC-Cy7-Streptavidin, FITC-CD45.1 and APC-CD45.2 antibodies were purchased from Biolegend (San Diego, CA, USA). The bone marrow biotin lineage panel and 7AAD/annexin-V staining kit were purchased from BD Pharmingen (Franklin Lakes, NJ, USA). All flow samples were analyzed by Canto-II or Fortessa flow cytometer and sorted by Aria-II cell sorter (BD Biosciences, Franklin Lakes, NJ, USA).
For phospho-flow, BM cells were stimulated with or without a cytokine cocktail, containing murine interleukin (IL)-3 (PeproTech, Rocky Hill, NJ, USA) 10 ng/ml, murine IL-6 (PeproTech) 10 ng/ml, murine stem cell factor (SCF) (PeproTech) 100 ng/ml and murine granulocyte-macrophage colonystimulating factor (BioLegend) 200 ng/ml for 15 min. Cells were then fixed in 1.5% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) at 37°C for 10 min and permeabilized on ice with methanol for 15 min. Subsequently, cells were stained with antibodies to cell surface markers, as well as to pERK1/2 (T202/Y204), pSTAT3 (Y705), pSTAT5 (Y694), pAKT (S473) or IgG isotope control for 30 min at room temperature, before being subjected to fluorescence-activated cell sorting analysis. All phospho-specific antibodies were purchased from eBiosciences and are phycoerythrin conjugated.
Bone marrow transplantation and induced deletion of p300/CBP Eight-week-old B6SJL-recipient mice were lethally irradiated (total body irradiation at 950 rads), and 6 h later, 2 × 10 6 donor BM cells were injected intravenously into each recipient mouse. Four weeks after transplantation, Mx1Cre-directed deletion of p300/CBP was induced by three intraperitoneal injections of poly(I:C) (10 μg/G body weight, Invivogen, San Diego, CA, USA), given every other day.
Paired daughter cell assay CD34
− LSK cells were sorted individually into 96-well plates with 150 μl of StemSpan Serum-Free Expansion Medium (Stem Cell Technology, Vancouver, BC, Canada) per well, supplemented with 100 ng/ml murine SCF and thrombopoietin. After overnight culture, if the single cell divided into two cells, the medium was vigorously mixed to separate the daughter cells. IMDM containing 10% fetal bovine serum plus murine SCF (100 ng/ml), thrombopoietin (100 ng/ml), granulocyte colony-stimulating factor (20 ng/ ml each), IL-3 (10 ng/ml) and erythropoietin (2 U/ml) was added to these wells to make the final volume to 200 μl/well. Plates were incubated for another 2 weeks (37°C/5% CO 2 ). Cytospins were prepared from the clones formed by each daughter pair. After Diff-Quick staining, symmetric selfrenewal divisions were determined by the presence of all four lineages (granulocyte, erythroid, megakaryocyte and monocyte) from each of the paired daughter cells. Symmetric commitment divisions were determined by the presence of three or less lineages from each of the paired daughter cells. Asymmetric self-renewal divisions were determined by the presence of three or less lineages from one daughter cell, but all four lineages from the other daughter cell.
Serial replating assay
A total of 1 × 10 4 BM Lin − c-kit + HSPCs were plated as duplicates in methylcellulose media (MethoCult GF M3434, Stem Cell Technologies). Colonies were scored 7 days after seeding; replating was conducted weekly.
RNA-sequencing and data analyses Sorted Lin
− c-kit + HSPCs were lysed in Trizol (Invitrogen, Carlsbad, CA, USA) and RNA was isolated and treated with DNase I as manufacturer's instruction. The quality of RNA was evaluated on an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), and samples with RNA integrity numbers 48.0 were prepared for sequencing. Poly(A)-tailed RNA was prepared by using messenger RNA-Sequencing Sample Preparation kit (Illumina, San Diego, CA, USA) and libraries for the deep-sequencing studies were generated by the Genomic Core Facility at the University of Miami. Sequencing and analysis were performed with three individual samples per group. Reads were aligned to the GRCm38/mm10 build of the Mus musculus genome with Subread aligner. We tested differentially expressed genes for enrichment in KEGG gene sets 20 in the Molecular Signature Database (MSigDB http://www.broadinstitute.org/gsea/msigdb/ index.jsp; version 5.0). Gene set enrichment analysis (GSEA) was conducted using the pre-ranked tool in gene set enrichment analysis software. 21 The RNA sequencing data has been deposited into NCBI SRA (Sequence Read Archive) database; the accession number is SRP092331.
Real-time PCR
RNA was extracted from BM cells and spleen cells using the RNeasy Mini or RNeasy Micro kit (Qiagen, Germantown, MD, USA). Complementary DNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Mouse Ep300 primers (Mm01310115_m1), Crebbp primers (Mm01342452_m1), Il3ra primers (Mm00434273_m1), Il4ra primers (Mm01275139_m1), Il6ra primers (Mm00439653_m1), Csf2rb primers (Mm00655745_m1) and Gapdh PCR primers (Mm99999915_g1) were purchased from Invitrogen. Quantitative PCR was performed on an ABI 7500 real-time cycler (Applied Biosystems Inc., Foster City, CA, USA). Data were analyzed by comparative CT method as 2
Statistical analysis
All data were analyzed by GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). For survival analysis, we plotted Kaplan-Meier curves and performed the log-rank (Mantel-Cox) test to assess the significance. The comparison of two groups or multiple groups was performed by unpaired t-test or analysis of variance with Tukey's multiple comparisons test. Significant differences are designated as *Po 0.05, **Po0.01, ***Po0.001 and ****Po0.0001.
RESULTS

Loss of p300 greatly accelerates the leukemogenesis of NHD13 BM cells
To evaluate the role of p300 and CBP in the progression of MDS disease, we utilized the well-studied, NHD13 transgenic mouse model of MDS. 22 Initially identified in therapy-related MDS, the NHD13 fusion protein induces murine MDS that recapitulates many key clinical features of human MDS, including peripheral blood cytopenias, bone marrow dysplasia with increased apoptosis and a significant risk of transformation to acute leukemia.
We crossed NHD13 transgenic mice with p300-or CBP-floxed mice; these mice were further crossed with Mx1Cre transgenic mice to generate NHD13 positive; p300 or CBP conditional KO mice. To determine p300/CBP function in MDS, we first performed BM transplantation using 2-month-old mice with the following genotypes as donors: NHD13;p300 flox/flox ;Mx1Cre − (referred to as NHD13 in figures), NHD13;p300 Figure S1A) . To our surprise, the mice that received NHD13;p300 flox/flox ;Mx1Cre + BM cells developed increased white blood cell counts and decreased platelet counts as early as 4 weeks post poly(I:C) injections (Supplementary Figure S1B) . Although all of the NHD13 mice developed MDS, with one-third of them died from MDS and one-third of them died from MDS-derived AML by week 40, all of the NHD13;p300 Δ/Δ --recipient mice died from AML by week 20, without a typical period of cytopenias ( Figure 1a ; Table 1 ). In contrast, loss of CBP in NHD13-expressing BM cells did not affect disease progression in the recipient mice. Furthermore, p300 deletion in wild-type (WT) BM cells had no obvious effect on the survival of recipient mice ( Figure 1a ; Table 1 ), as all mice were disease-free 40 weeks post poly(I:C) injection.
The leukemic NHD13;p300 Δ/Δ mice had markedly enlarged spleens, increased WBC counts, and decreased red blood cell and platelet counts compared with age-matched NHD13 mice Figure 1b ). Immunostaining and flow cytometry showed an expanded c-kit + population, whereas Giemsa staining of BM cytospin showed a significant increase in leukemic blasts (Supplementary Fig S1C) . p300 loss expands the HSPC population in NHD13 mice To better understand the acceleration of leukemogenesis observed in p300-deleted NHD13 mice, we analyzed the BM HSPC compartment in all recipient mice two weeks after the poly(I:C) injection, when there was no obvious sign of MDS or leukemia. Loss of p300 rapidly altered the BM compartment of the NHD13 mice with a marked expansion of both Lin Figure S1D) .
To exclude any potential influence of the BM ablation that follows lethal irradiation on HSPC behavior and disease progression, we performed similar experiments using primary mice, and the same genotypes as used for the transplantation experiments. Mice were injected with poly(I:C) at the pre-MDS stage (2 months of age) and followed for 40 weeks. We confirmed the survival pattern seen in the BM transplantation model, as loss of p300 accelerated leukemogenesis and impaired survival, while the loss of CBP did not alter disease progression or the survival of the NHD13 mice (Supplementary Figure S2A) . The expansion of both LK and LSK population was similar to that seen in the transplanted models (Supplementary Figure S2B) , including the absence of any change in the HSPC compartment when CBP was deleted in the primary NHD13 mice (Supplementary Figure S2C) . In addition, we have also performed the bone marrow transplantation experiments using leukemia cells isolated from primary NHD13, NHD13; p300 Δ/Δ and NHD13;CBP Δ/Δ mice, and found that leukemias from all three genotypes are all transplantable to secondary recipient mice (data not shown).
Loss of p300 enhances NHD13 HSPC self-renewal To understand the basis for the p300-deleted NHD13 HSPC expansion, we performed serial replating assays using HSPCs isolated from transplant recipient mice (Figure 2a ) or primary mice (Figure 2b ) 2 weeks after poly(I:C) injection. In both cases, the NHD13;p300 Δ/Δ HSPCs showed increased self-renewal, which was particularly evident after the third replating. As expected, HSPCs from the NHD13 mice had little ability to form colonies in semisolid culture media. Loss of p300 only minimally affected colony formation of WT cells, confirming the unique role of p300 in NHD13-expressing HSPCs.
To further our understanding of the improved self-renewal of the NHD13;p300 Δ/Δ HSPCs, we performed paired daughter cell assays in vitro using sorted CD34 − LSK cells obtained 2 weeks after the poly(I:C) injection. Cytospins were prepared from the clones formed by each daughter pair, and the frequency of symmetric vs asymmetric division was quantified (Figure 2c ). Symmetric commitment divisions were dominant in NHD13 CD34 − LSK cells (50%) compared with WT (28%), p300 Δ/Δ (22%) or NHD13;p300 Δ/Δ (14%) CD34 − LSK cells; in contrast symmetric self-renewal divisions were over-represented in the NHD13;p300 Δ/Δ HSCs (68%) comparing to the WT (31%), p300 Δ/Δ (48%) or NHD13 (28%) cells. Altogether, these data indicate a crucial role for p300 in controlling the balance of symmetric stem cell self-renewing divisions vs. stem cell depleting divisions in NHD13 mice.
Deletion of p300 decreases apoptosis in NHD13 BM cells To further clarify the effect of p300 deletion on NHD13-expressing BM cells, we determined their proliferation and apoptosis 2 weeks after poly(I:C) injection. Using BM cells isolated from primary mice, we found that loss of p300 reduced the elevated apoptotic rate in NHD13-transduced BM cells, especially in the stem cell-enriched LSK cells (Figure 2d ). In contrast, p300 deletion had little if any effect on the proliferation of WT or NHD13-positive BM cells (Supplementary Figure S3) . Thus, loss of p300 led to unique alterations in the survival of NHD13-expressing BM cells, which would be expected to contribute to leukemia progression.
RNA-sequencing analysis reveals a unique gene signature in p300-null NHD13 HSPCs To further understand how loss of p300 promotes leukemogenesis, we also purified HSPCs from WT, NHD13, p300
Δ/Δ and NHD13; p300 Δ/Δ primary mice 2 weeks after the poly(I:C) injection and from NHD13;p300 Δ/Δ mice at the leukemia stage, and prepared RNA samples for comparative RNA-sequencing analysis. We initially normalized the expression profiles of the top 100 genes with the largest s.d.'s across all samples by comparing each to the WT HSPCs and noticed many similarities between the WT, p300 Δ/Δ and NHD13 samples (Figure 3a) . In contrast, the NHD13;p300 Δ/Δ HSPCs exhibited a unique profile at the pre-AML, but also at the leukemic stage, indicating a specific interaction between p300 and NHD13 in HSPCs. Consistent with this notion, we found that p300 deletion affected significantly more genes in the NHD13 HSPCs than in the WT HSPCs (2612 vs 545), with only 148 genes being commonly affected by p300 deletion in both genotypes (Figure 3b ). Using unbiased, gene set enrichment analysis, we identified three upregulated pathways that were directly related to hematopoiesis, including the cytokine/cytokine receptor interaction pathway (Figure 3c ). Downregulated pathways included several pathways thought to be involved in malignant transformation, such as RNA splicing, oxidative phosphorylation and mismatch repair. [23] [24] [25] Given the flurry of papers reporting the abnormal expression of cytokine receptors on MDS/AML-initiating stem cells, [26] [27] [28] [29] we performed quantitative PCR assays for several genes, including Il3ra, Il4ra, Il6ra and Csf2rb to validate the RNA-seq data, and we observed highly correlated data showing the upregulation of these cytokine receptors (Figure 3d; Supplementary Figure S4A) , which could help drive leukemogenesis in the p300-deleted NHD13 mice. In contrast, loss of CBP had no obvious impact on the expression of these cytokine receptors, except for Il4ra (Supplementary Figure S4B) . p300 deletion enhances cytokine signaling in NHD13 HSPCs Aberrant cytokine signaling occurs in a variety of malignancies, 30 with activation of JAK/STAT signaling commonly underlying hematopoietic cell transformation. 31 To further explore cytokine signaling, we performed the phospho-flow analyses, using BM cells isolated from mice 2 weeks post poly(I:C) injection. As shown in Figures 4a-c , loss of p300, but not CBP, enhanced phosphorylation of ERK1/2 and STAT5 in response to cytokine stimulation in Figure 3 . Differentially expressed genes in p300-null NHD13 HSPCs. HSPCs were isolated from the indicated primary mice and sorted 2 weeks after poly(I:C) injection. Lin − and c-kit + cells were also isolated from NHD13;p300 Δ/Δ mice at leukemia stage. RNA samples were then prepared for RNA-sequencing analyses. (a) Normalized expression profiles of the top 100 genes with the largest standard deviations across all samples, including samples from the leukemic NHD13;p300 Δ/Δ mice. Data represented are variance-stabilizing transformation counts from the DESeq2 package (Illumina). The dendrogram shows samples in all groups clustered as expected. (b) Venn diagram shows the overlap of differentially expressed genes in p300-deleted WT vs NHD13 mice. Genes were considered to be differentially expressed if they had a P-value of o0.05 and absolute log fold change of 41.5. (c) Up-and downregulated pathways identified using gene set enrichment analysis after p300 deletion in NHD13 HSPCs. (d) Quantitative PCR validation for several differentially expressed genes. Data were normalized to the expression of GAPDH. *P o0.05; ***P o0.001. . *Po0.05; **P o0.01; ***P o0.001 and ****P o0.0001.
p300 regulates MDS to leukemia transformation G Cheng et al both WT and NHD13-transformed LK and LSK cells. This suggests that p300 can function to repress cytokine signaling in HSPCs. Given the importance of STAT3 signaling in HSC self-renewal, 32 it is intriguing to see that p300 deletion markedly upregulated the STAT3 signaling pathway specifically in NHD13 transformed, but not WT LSK cells. In contrast, we failed to see any change in AKT phosphorylation after p300 deletion in HSPCs of all genotypes we tested (Supplementary Figure S5) .
DISCUSSION
We report here that loss of p300 significantly accelerated the transformation of NHD13 BM cells, identifying p300 as a tumor suppressor in NHD13-driven leukemogenesis, which is quite distinct from its role in promoting AML1-ETO-associated leukemogenesis. 33 Mechanistically, loss of p300 enhanced selfrenewal and reduced apoptosis in NHD13 BM cells; in contrast, loss of p300 did not significantly alter WT hematopoiesis, indicating the cell context-dependent role of p300. An earlier study of NUP98-HOXA9-associated blast crisis chronic myeloid leukemia and AML reported a shift from asymmetric stem cell divisions to symmetric self-renewing divisions and proposed that this shift could lead to disease progression. 34 Similarly, the increase in symmetric self-renewal divisions (68% vs 28%) that follows the deletion of p300 in NHD13-expressing HSCs may underlie the profoundly increased risk for leukemogenesis in these mice.
Loss of p300 triggered a unique gene signature in both NHD13-expressing and NHD13-transformed HSPCs, including the upregulation of the cytokine/cytokine receptor interaction pathway. Although this pathway is crucial for normal HSPC biology, it is co-opted in myeloid leukemia cells with inappropriate activation of cytokine signaling, resulting from the overexpression or constitutive activation of receptor tyrosine kinases, such as c-KIT, FLT3 and IL-3Rα. 35 The NHD13;p300 Δ/Δ HSPCs have increased expression of several cytokine receptors, including IL-3Rα, IL-4Rα, IL-6Rα and CSFRβ, which activate the MAPK, PI3K/AKT and JAK/STAT pathways in response to cytokines. 36 We found significantly increased MAPK and JAK/STAT activation in NHD13; p300 Δ/Δ BM cells. Although PI3K/AKT pathway is also downstream of these receptors, it is not affected by p300 deletion, indicating that other mechanism(s) play a more important role in regulating this signaling pathway. It appears that the elevated cytokine signaling that follows the loss of p300 in NHD13 BM confers a growth advantage to pre-leukemic blasts.
Both p300 and CBP were recently shown to facilitate leukemogenesis in cooperation with MOZ-TIF2 and NUP98-HOXA9. 37 In the NHD13 MDS model, p300 acts to prevent the transformation to AML, although loss of CBP has no effect on disease progression. Even though these two proteins are highly homologous, p300 and CBP appear to have non-redundant functions in NHD13-mediated leukemogenesis, and it will likely take a combined proteomics and expression profiling approach to better understand how p300 differs from CBP in modifying the epigenetic landscape and controlling this transition.
